Syn X Pharma, Inc.

Nanogen, Inc.

Other

Artemis Proteomics, Ltd.

The University of Waterloo

Yyz Pharmatech, Inc.

John G Marshall

George Jackowski

Jason Yantha

Brad Thatcher

Tammy Vrees

Weimin Zhu

Rulin Zhang

Erwin B Dumbroff

Christopher Smith

Lesley G Campbell

Angelica Kirsten Florentinus

Disclosed are effective methods for activating, washing, specifically extracting and purifying cannabinoids fromplant tissues using heat activation, washing impurities away with a polar solvent, optionally modified with an organic acid, base, surfactant or inorganic salt, extracting the activated non-polar cannabinoids with a potable selective solvent such as ethanol. The extracted active ingredients may be purified by chromatography and detected and quantified by mass spectrometry with external or isotopic or otherwise labelled standards.

Extraction and purification of cannabinoid compounds

Disclosed are sensitive methods for detecting a target substance in low concentrations. The method can include immobilizing a target substance to a solid phase; incubating the immobilized target substance with a reporter enzyme detection probe in solution under conditions for forming target: enzyme detection probe complexes; washing the solid phase to remove any unbound reporter enzyme detection probe; incubating the target: enzyme detection probe complex with a reporter enzyme detection probe substrate in substrate reaction solution to generate one or more ionizable products; and detecting one or more of the one or more ionizable products using mass spectrometry (MS).

Methods and compositions for enzyme linked immuno and hybridization mass spectrometric assay

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer, predict disease risk assessment, and develop therapeutic avenues against said disease.

Interalpha trypsin inhibitor biopolymer markers indicative of insulin resistance

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or the absence of at least one disease state relative to recognition of the presence and/or the absence of the biopolymer, predict disease risk assessment, and develop therapeutic avenues against the disease.

Apolipoprotein biopolymer markers indicative of insulin resistance

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and/or the absence of the biopolymer.

Biopolymer marker indicative of disease state having a molecular weight of 1562 daltons

Biopolymer marker indicative of disease state having a molecular weight of 1348 daltons

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and/or the absence of a biopolymer.

Biopolymer marker indicative of disease state having a molecular weight of 1525 Daltons

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and/or the absence of the biopolymer, predict disease risk assessment, and develop therapeutic avenues against the disease.

Complement C3 precursor biopolymer markers indicative of insulin resistance

Fibronectin precursor biopolymer markers indicative of alzheimer's disease

IG heavy chain, IG kappa, IG lambda biopolymer markers predictive of Alzheimer's disease

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and/or the absence of the biopolymer, predict disease risk assessment, and develop therapeutic avenues against disease.

Protein biopolymer markers indicative of insulin resistance

Betaine/GABA transport protein biopolymer marker indicative of insulin resistance

Method and kit for diagnosing myocardial infarction

Protein biopolymer markers predictive of type II diabetes

Biopolymer markers indicative of type II diabetes

Growing community of inventors

Toronto, Canada

John G Marshall